Person:
ALKIŞ, HİLAL

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ALKIŞ

First Name

HİLAL

Name

Filters

2013 - 20198
Reset filters

Settings

End date: 2019 × Start date: 2013 ×

Search Results

Now showing 1 - 8 of 8
  • No Thumbnail Available
    PublicationMetadata only
    Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer
    (SPRINGER INTERNATIONAL PUBLISHING AG, 2019) DANE, FAYSAL; Ercelep, O.; Alan, O.; Sahin, D.; Telli, T. A.; Salva, H.; Tuylu, T. B.; Babacan, N. A.; Kaya, S.; Dane, F.; Ones, T.; Alkis, H.; Adli, M.; Yumuk, F.
    PurposeThe standard treatment for patients with stage III non-small cell lung cancer (NSCLC), unsuitable for resection and with good performance, is definitive radiotherapy with cisplatin-based chemotherapy. Our aim is to evaluate the effect of the maximum value of standardized uptake values (SUVmax) of the primary tumor in positron emission tomography-computed tomography (PET/CT) before treatment on complete response (CR) and overall survival.MethodsThe data of 73 stage III NSCLC patients treated with concurrent definitive chemoradiotherapy (CRT) between 2008 and 2017 and had PET/CT staging in the pretreatment period were evaluated. ROC curve analysis was performed to determine the ideal cut-off value of pretreatment SUVmax to predict CR.ResultsMedian age was 58years (range 27-83years) and 66 patients were male (90.4%). Median follow-up time was 18months (range 3-98months); median survival was 23months. 1-year overall survival (OS) rate and 5-year OS rate were 72 and 19%, respectively. Median progression-free survival (PFS) was 9months; 1-year PFS rate and 5-year PFS rate were 38 and 19%, respectively. The ideal cut-off value of pretreatment SUVmax that predicted the complete response of CRT was 12 in the ROC analysis [AUC 0.699 (0.550-0.833)/P<0.01] with a sensitivity of 83%, and specificity of 55%. In patients with SUVmax<12, CR rate was 60%, while, in patients with SUV12, it was only 19% (P=0.002). Median OS was 26months in patients with pretreatment SUVmax<12, and 21months in patients with SUVmax12 (HR=2.93; 95% CI 17.24-28.75; P=0.087). CR rate of the whole patient population was 26%, and it was the only factor that showed a significant benefit on survival in both univariate and multivariate analyses.ConclusionPretreatment SUVmax of the primary tumor in PET/CT may predict CR in stage III NSCLC patients who were treated with definitive CRT. Having clinical CR is the only positive predictive factor for prolonged survival.
  • Thumbnail Image
    PublicationOpen Access
    Tumor Response after Preoperative Chemoradiation Therapy with Simultaneous Integrated Boost Using Volumetric Modulated Arc Therapy in Locally Advanced Rectal Cancer
    (ELSEVIER SCIENCE INC, 2019-09) DEVRAN, BENNUR ZEYNAN; Adli, M.; Alkis, H.; Gulegen, B. Z.; Halil, S.; Degerli, A. Dagli; Ozturk, F.; Atalay, V.; Yegen, C.
  • No Thumbnail Available
    PublicationMetadata only
    Mide kanserinde radyoterapi
    (Türkiye Klinikleri Tıp Bilimleri Dergisi, 2019-01-01) ADLI, MUSTAFA; ALKIŞ, HİLAL; ADLI M., ALKIŞ H.
  • No Thumbnail Available
    PublicationMetadata only
    Neoadjuvan radyoterapi uygulanan rektum kanserlerinde VMAT ile simültane entegre boost'un normal organ dozlarına etkisi
    (2018-05-01) ALKIŞ, HİLAL; ADLI, MUSTAFA; DAĞLI A., ASADOLLAHI ARBATANI A., AKAY S. U., ALKIŞ H., RZAZADE R., SAHİBOV E., YÖNDEM İNAL S., ADLI M.
  • Thumbnail Image
    PublicationOpen Access
    Predicting Tumor Stage (pT) Using Preoperative FDG Positron Emission Tomography Uptake in Patients With Invasive Ductal Carcinoma of the Breast
    (ELSEVIER SCIENCE INC, 2016-10) ALKIŞ, HİLAL; Adli, M.; Koc, M.; Sevindik, M.; Rzazade, R.; Arbatani, A. Asadollahi; Kaya, S.; Sahibov, E.; Alkis, H.
  • No Thumbnail Available
    PublicationMetadata only
    Mide kanserinde radyoterapi
    (Türkiye Klinikleri, 2019-01-01) ADLI, MUSTAFA; ALKIŞ, HİLAL; ADLI M., ALKIŞ H.
  • No Thumbnail Available
    PublicationMetadata only
    Güneydoğu Anadolu Bölgesinde yaşayan meme kanseri tanılı hastalarda hormon reseptör durumunun etnisiteye göre dağılımı
    (2013-04-23) ALKIŞ, HİLAL; ADLI, MUSTAFA; KUZHAN A., ALKIŞ H., ADLI M., ÇAĞLAYAN D.
  • Thumbnail Image
    PublicationOpen Access
    FDG PET Uptake as a Predictor of Pain Response in Palliative Radiation Therapy in Patients with Bone Metastasis
    (RADIOLOGICAL SOC NORTH AMERICA, 2013-12) ALKIŞ, HİLAL; Adli, Mustafa; Kuzhan, Abdurrahman; Alkis, Hilal; Andic, Fundagul; Yilmaz, Mustafa
    Purpose: To evaluate the relationship between fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) maximum standardized uptake value (SUVmax) and pain response to radiation therapy (RT) in patients with bone metastasis. Materials and Methods: Institutional ethical board approval for the study was obtained, with informed consent, for this prospective study. Thirty-one patients with metastatic bone pain who underwent FDG PET/computed tomography before RT were included. Patients were diagnosed with lung (n = 16), breast (n = 7), stomach (n = 2), and head and neck cancers (n = 3), as well as unknown primary tumor (n = 3). Eighty-five painful metastatic locations with FDG PET scans geographically corresponding to 40 treatment fields were evaluated. Pain scores using visual analog scale or faces pain rating scale and SUVmax at each location were recorded. All patients were treated with a single fraction 8 Gy RT. Pain scores after RT were assessed at weeks 2, 4, 8, 12, 16, 20, and 24. The pretreatment pain scores and pain response to RT were compared with FDG PET SUVmax of each location. Pearson correlation, independent t test, one-way analysis of variance, and chi(2) tests were used for statistical analysis. Results: Median SUVmax and initial pain scores for all locations were 7.2 (range, 1.5-22.5) and 6 (range, 2-8), respectively. Median follow-up time was 24 (range, 3-112) weeks. Median SUVmax was 4.5 (range, 3.1-7.3), 4.75 (range, 1.5-10.3), 8.8 (range, 5.2-11.9), and 12.1 (range, 7-22.5) for pretreatment pain scores of 2, 4, 6, and 8, respectively. SUVmax was correlated with pretreatment pain scores (P < .0001). SUVmax and pretreatment pain scores were also significantly associated with pain response to RT. Median SUVmax for locations with complete response, partial response, pain progression, and indeterminate response was 5.2, 9.75, 10.8, and 6.4, respectively (P <= .001). Conclusion: FDG PET SUVmax correlated with initial pain severity and pain response to RT and can be used as a predictive factor for treatment response in patients with painful bone metastasis treated with palliative RT. (C) RSNA, 2013